Mario Sznol, MD

Professor of Medicine (Medical Oncology); Co-Director, Yale SPORE in Skin Cancer

Clinical Interests

  • Medical Oncology
  • Melanoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Cancer Center: Melanoma Program | Prostate & Urologic Cancers Program

General Adult Urology

Urologic Oncology Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Internal Medicine AB of Internal Medicine (1985)

  • Medical Oncology AB of Internal Medicine (1987)

Clinical Trials

Conditions Study Title
Kidney, Melanoma, skin A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Melanoma, skin A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies
Phase I, Colon, Melanoma, skin An Open-Label, Multicenter, Dose Escalation and Expansion Phase 1B Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Activity of RO6958688 in Combination with Atezolizumab in Patients with Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Kidney, Melanoma, skin A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Melanoma, skin A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Brain and Nervous System, Lung, Melanoma, skin A Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Kidney, Melanoma, skin A Phase I/II, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Melanoma, skin A Phase II, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach, Phase I A Study of MPDL3280A Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Lung, Melanoma, skin MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Melanoma, skin Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic
Other Skin A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Kidney Active Surveillance of the Small Renal Mass
Melanoma, skin A Phase I, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3)
Kidney, Phase I A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors
Soft Tissue, Phase I Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Edit this profile

Contact Info

Mario Sznol, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 8

New Haven, CT 06511
View on map...
Mailing Address
PO Box 208028
333 Cedar Street

New Haven, CT 06520-8028